226 related articles for article (PubMed ID: 32926247)
1. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial.
Reveille JD; Hwang MC; Danve A; Kafka S; Peterson S; Lo KH; Kim L; Hsia EC; Chan EKH; Deodhar A
Clin Rheumatol; 2021 Apr; 40(4):1331-1341. PubMed ID: 32926247
[TBL] [Abstract][Full Text] [Related]
2. The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial.
Ogdie A; Walsh JA; Chakravarty SD; Peterson S; Lo KH; Kim L; Li N; Hsia EC; Chan EKH; Kavanaugh A; Husni ME
Clin Rheumatol; 2021 Sep; 40(9):3667-3677. PubMed ID: 33655380
[TBL] [Abstract][Full Text] [Related]
3. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial.
Reveille JD; Deodhar A; Ince A; Chan EKH; Peterson S; Li N; Hsia EC; Kim L; Lo KH; Xu S; Harrison DD; Han C
Value Health; 2020 Oct; 23(10):1281-1285. PubMed ID: 33032770
[TBL] [Abstract][Full Text] [Related]
4. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.
van der Heijde D; Deodhar A; Braun J; Mack M; Hsu B; Gathany TA; Inman RD; Han C;
J Rheumatol; 2014 Jun; 41(6):1095-103. PubMed ID: 24737912
[TBL] [Abstract][Full Text] [Related]
5. Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
Deodhar A; Shiff NJ; Gong C; Chan EKH; Hsia EC; Lo KH; Akawung A; Kim L; Xu S; Reveille JD
Rheumatol Ther; 2023 Aug; 10(4):983-999. PubMed ID: 37322274
[TBL] [Abstract][Full Text] [Related]
6. Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1).
Deodhar AA; Dougados M; Baeten DL; Cheng-Chung Wei J; Geusens P; Readie A; Richards HB; Martin R; Porter B
Arthritis Rheumatol; 2016 Dec; 68(12):2901-2910. PubMed ID: 27390130
[TBL] [Abstract][Full Text] [Related]
7. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
Bingham CO; Weinblatt M; Han C; Gathany TA; Kim L; Lo KH; Baker D; Mendelsohn A; Westhovens R
J Rheumatol; 2014 Jun; 41(6):1067-76. PubMed ID: 24786931
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.
Reveille JD; Deodhar A; Caldron PH; Dudek A; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
J Rheumatol; 2019 Oct; 46(10):1277-1283. PubMed ID: 30824635
[TBL] [Abstract][Full Text] [Related]
9. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
Boonen A; Patel V; Traina S; Chiou CF; Maetzel A; Tsuji W
J Rheumatol; 2008 Apr; 35(4):662-7. PubMed ID: 18278836
[TBL] [Abstract][Full Text] [Related]
10. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial.
Navarro-Compán V; Wei JC; Van den Bosch F; Magrey M; Wang L; Fleishaker D; Cappelleri JC; Wang C; Wu J; Dina O; Fallon L; Strand V
RMD Open; 2022 Jun; 8(2):. PubMed ID: 35654457
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.
Bao C; Huang F; Khan MA; Fei K; Wu Z; Han C; Hsia EC
Rheumatology (Oxford); 2014 Sep; 53(9):1654-63. PubMed ID: 24729398
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study.
Deodhar A; Reveille JD; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
J Rheumatol; 2018 Mar; 45(3):341-348. PubMed ID: 29247154
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
Curtis JR; McInnes IB; Rahman P; Gladman DD; Yang F; Peterson S; Agarwal P; Kollmeier AP; Hsia EC; Han C; Shiff NJ; Shawi M; Tillett W; Mease PJ
Adv Ther; 2022 Oct; 39(10):4632-4644. PubMed ID: 35947348
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study.
Deodhar AA; Shiff NJ; Gong C; Hsia EC; Lo KH; Kim L; Xu S; Reveille JD
J Clin Rheumatol; 2022 Aug; 28(5):270-277. PubMed ID: 35653615
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.
Kavanaugh A; McInnes IB; Krueger GG; Gladman D; Beutler A; Gathany T; Mack M; Tandon N; Han C; Mease P
Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1666-73. PubMed ID: 23666608
[TBL] [Abstract][Full Text] [Related]
16. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial.
Husni ME; Kavanaugh A; Chan EKH; Peterson S; Li N; Hsia EC; Kim L; Lo KH; Harrison DD; Han C
Value Health; 2020 Oct; 23(10):1286-1291. PubMed ID: 33032771
[TBL] [Abstract][Full Text] [Related]
17. Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials.
Gensler LS; Chakravarty SD; Cameron C; Peterson S; Spin P; Kafka S; Nair S; Deodhar A
Clin Rheumatol; 2020 Oct; 39(10):2907-2917. PubMed ID: 32367407
[TBL] [Abstract][Full Text] [Related]
18. Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis.
Curtis JR; McInnes IB; Rahman P; Gladman DD; Peterson S; Yang F; Adejoro O; Kollmeier AP; Shiff NJ; Han C; Shawi M; Tillett W; Mease PJ
Rheumatol Ther; 2024 Apr; 11(2):425-441. PubMed ID: 38386178
[TBL] [Abstract][Full Text] [Related]
19. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Husni ME; Deodhar A; Schwartzman S; Chakravarty SD; Hsia EC; Leu JH; Zhou Y; Lo KH; Kavanaugh A
Arthritis Res Ther; 2022 Mar; 24(1):73. PubMed ID: 35313978
[TBL] [Abstract][Full Text] [Related]
20. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.
Inman RD; Baraliakos X; Hermann KA; Braun J; Deodhar A; van der Heijde D; Xu S; Hsu B
Arthritis Res Ther; 2016 Dec; 18(1):304. PubMed ID: 28031053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
